Who Paid My Doc
Jonathan Lenzen
Critical Care Medicine Jasper, TN Medical Doctor
NPI 1275502510 CMS profile 427566
3697 Main St, Jasper, TN 37347
General payments
$2,262
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Jonathan Lenzen of Jasper, TN is reported in the CMS Open Payments database as having received $2,262 across 107 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 77th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $689 | 32 | |
| 2022 | General | $591 | 25 | |
| 2021 | General | $553 | 18 | |
| 2020 | General | $177 | 14 | |
| 2019 | General | $252 | 18 |
Beside peers
- Jonathan Lenzen
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Jonathan Lenzen were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Jonathan Lenzen | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $252 | $149 | $51–$535 | $163 |
| 2020 | $177 | $110 | $30–$325 | $114 |
| 2021 | $553 | $125 | $34–$403 | $132 |
| 2022 | $591 | $157 | $49–$582 | $149 |
| 2023 | $689 | $162 | $56–$621 | $160 |
| 2024 | $0 | $168 | $53–$634 | $164 |
| 2025 | $0 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
89
Drug cost
$181,699
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | Brand | 12 | $158,821 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 32 | $21,701 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 45 | $1,178 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Records
107 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Tennessee
Gordon Bernard
Critical Care Medicine · Nashville, TN
Todd Rice
Critical Care Medicine · Nashville, TN
Jeffery Nelson
Critical Care Medicine · Maryville, TN
Jeremy Greenberg
Critical Care Medicine · Chattanooga, TN
Anthony Mattox
Critical Care Medicine · Memphis, TN
Ann Gage
Critical Care Medicine · Nashville, TN
Related records
Critical Care Medicine in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.